In this video, Anjay Rastogi, MD, PhD, professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, discusses treatment options for chronic kidney disease patients with ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...

A new study used German data to assess the effects of CKD, anemia, or both on the development and eventual progression of HF among at-risk and symptomatic patients. The prevalence and severity of CKD ...

dementia Additional studies are needed to determine whether anemia itself is a risk factor for dementia in the CKD population. Anemia in patients with chronic kidney disease (CKD) portends an ...

Authors of a recent review explored the complex relationship between CKD, COVID-19, and anemia and offered practice points based on clinical experience. Patients with chronic kidney disease (CKD) ...

Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease. Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...

daily multivitamin does not reduce the risks of cvd in men Iron therapy and erythropoiesis-stimulating agents are not always effective for anemia in patients with CKD. Nutritional interventions may be ...

Credit: Getty Images. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the treatment of ...

November 14, 2008 — Preventing anemia may improve quality of life (QofL) in patients with kidney disease, according to the results of a cross-sectional study published online November 5, 2008, in the ...

In this study, both anemia and chronic kidney disease were highly prevalent among HF patients discharged from two university hospitals and independently associated with an increased risk of dying in ...

(RTTNews) - The U.S. Food and Drug Administration conditionally approved Elanco US Inc.'s Varenzin-CA1 (molidustat oral suspension) for treating anemia in cats with chronic kidney disease or CKD. It ...